RxDoctor Payments Data

Margret Jones, NP

Family · Augusta, GANPI 1568944072

Payments from drug & device makers

$1,921in general payments, 2019–2025

Across 68 payments — averaging $28.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$505
  • Novartis$255
  • Cvrx, Inc.$254
  • Medtronic$226
  • Pfizer$183
  • Amgen$123
  • plus $375 from 8 others

What the payments were for

  • Food & beverage$1,80794%
  • Education$1146%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,921 in reported general payments places this provider in the 75th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$15,113
Medicare patients
84
Services billed
287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan149$211,327
JardianceEmpagliflozin85$82,847
FarxigaDapagliflozin Propanediol61$65,812
EliquisApixaban63$61,089
Eplerenone29$2,672
Digoxin23$2,142
Metoprolol Succinate174$2,078
Spironolactone172$1,128
Potassium Chloride64$871
Atorvastatin Calcium92$645
Carvedilol81$545
Furosemide100$488
Valsartan21$457
Torsemide22$392
Hydralazine Hcl31$277

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$255$211,327149 claims
Boehringer IngelheimJardiance$73$82,84785 claims
AstraZenecaFarxiga$505$65,81261 claims
PfizerEliquis$183$61,08963 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 6,258 family providers in Georgia.

Other family in Augusta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →